

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Genscript Biotech Corporation**

**金斯瑞生物科技股份有限公司\***

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock code: 1548)**

**VOLUNTARY ANNOUNCEMENT  
ACQUISITION OF 100% OF THE ENTIRE ISSUED SHARES OF  
CUSTOMARRAY, INC.**

This is a voluntary announcement made by the Company.

**THE ACQUISITION**

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that on 25 December 2017, (i) the Buyer, (ii) the Company, (iii) the selling shareholders, (iv) the shareholders’ representative, and (v) the Target Company entered into a stock purchase agreement (the “**Stock Purchase Agreement**”), pursuant to which the Buyer agreed to acquire 100% of the entire issued shares of the Target Company from the selling shareholders (the “**Acquisition**”).

Completion is subject to fulfillment of various conditions precedent set out in the Stock Purchase Agreement.

**INFORMATION ON THE TARGET COMPANY AND THE SELLING SHAREHOLDERS**

The Target Company is incorporated in the State of Washington of United States of America and is a provider of oligo pools to many of the world’s leading academic and industrial organizations for applications including targeted sequencing, complex DNA libraries, synthetic biology, shRNA libraries, and CRISPR. The patented, in situ synthesis of oligonucleotide microarrays uses advanced semiconductor technology to enable the synthesis of tens of thousands of oligonucleotides simultaneously.

To the best of the knowledge, information and belief of the Directors, having made all reasonable enquiries, all of the selling shareholders are third parties independent of the Company and its connected persons as at the date of this announcement.

## **INFORMATION ON THE GROUP AND THE BUYER**

The Group is principally engaged in the provision of (i) life sciences research services, (ii) life sciences research catalog products, (iii) preclinical drug development services, and (iv) industrial synthetic biology products.

The Buyer is a company incorporated under the laws of the State of Delaware of the United States, which is a wholly owned subsidiary of the Company.

## **LISTING RULES IMPLICATIONS**

As all the relevant percentage ratios under Chapter 14 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) for the Acquisition are less than 5%, the Acquisition is exempt from the requirements under Chapter 14 of the Listing Rules.

This announcement is made by the Company voluntarily for the purpose of keeping the potential investors and shareholders of the Company informed of the latest business development of the Group.

**Shareholders and potential investors of the Company should note that Completion is subject to the fulfillment of the conditions precedent set out in the Stock Purchase Agreement and therefore may or may not occur. As the Acquisition may or may not proceed to Completion, shareholders and potential investors of the Company are reminded to exercise caution when dealing in the securities of the Company.**

## **DEFINITIONS**

“Buyer”	Genscript USA Holding Inc., a company incorporated under the laws of the State of Delaware of the United States, which is a wholly owned subsidiary of the Company
“Company”	Genscript Biotech Corporation (金斯瑞生物科技股份有限公司), an exempted company incorporated under the laws of the Cayman Islands with limited liability and whose shares are listed and traded on the Main Board of The Stock Exchange of Hong Kong Limited

“Completion”	the completion of the Acquisition
“Group”	Company and its subsidiaries
“Target Company”	CustomArray, Inc., a company incorporated in the State of Washington of the United States of America

By order of the Board  
**Genscript Biotech Corporation**  
**Zhang Fangliang**  
*Chairman and Chief Executive Officer*

Hong Kong, 27 December 2017

*As at the date of this announcement, the executive Directors are Dr. Zhang Fangliang, Ms. Wang Ye and Mr. Meng Jiange; the non-executive Directors are Dr. Wang Luquan, Mr. Huang Zuie-Chin and Mr. Pan Yuexin; and the independent non-executive Directors are Mr. Guo Hongxin, Mr. Dai Zumian and Ms. Zhang Min.*

\* *For identification purposes only*